April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Retinal Functional Improvement With Nano-laser Treatment In High Risk Early Age-related Macular Degeneration
Author Affiliations & Notes
  • Robyn H. Guymer
    Ctr for Eye Rsch - AU, University of Melbourne, East Melbourne, Australia
  • Kate Brassington
    Ctr for Eye Rsch - AU, University of Melbourne, East Melbourne, Australia
  • Peter N. Dimitrov
    Ctr for Eye Rsch - AU, University of Melbourne, East Melbourne, Australia
  • Mary Varsamidis
    Ctr for Eye Rsch - AU, University of Melbourne, East Melbourne, Australia
  • Galina Makeyeva
    Ctr for Eye Rsch - AU, University of Melbourne, East Melbourne, Australia
  • Khin Zaw Aung
    Ctr for Eye Rsch - AU, University of Melbourne, East Melbourne, Australia
  • Devinder Chauhan
    Vision Retinal Institute, Box Hill Vic. 3128, Box Hill Vic. 3128, Australia
  • Algis Vingrys
    University of Melbourne, Optometry & Vision Sciences, Carlton, Australia., Australia
  • Chi Luu
    Ctr for Eye Rsch - AU, University of Melbourne, East Melbourne, Australia
  • Footnotes
    Commercial Relationships  Robyn H. Guymer, None; Kate Brassington, None; Peter N. Dimitrov, None; Mary Varsamidis, None; Galina Makeyeva, None; Khin Zaw Aung, None; Devinder Chauhan, None; Algis Vingrys, None; Chi Luu, None
  • Footnotes
    Support  This work was supported in part by the Victorian Government Department of Innovation, Industry and Regional Development, the Australian Government Department of Industry and Resources and Ellex R & D Pt
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1670. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robyn H. Guymer, Kate Brassington, Peter N. Dimitrov, Mary Varsamidis, Galina Makeyeva, Khin Zaw Aung, Devinder Chauhan, Algis Vingrys, Chi Luu; Retinal Functional Improvement With Nano-laser Treatment In High Risk Early Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1670.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

The aim of this pilot study was to show if a novel nanosecond laser (2RT) treatment could improve visual function and reduce drusen in high risk Early Age-related Macular Degeneration (AMD), which may then lead to reduced risk of late stage AMD.

 
Methods:
 

Interim results out t o12 months from a prospective pilot study (ACTRN12609001056280). Early AMD patients selected with high risk Early AMD but without choroidal neovascularization (CNV) or geographic atrophy (GA). Patients examined with visual field perimeter, optical coherence tomography (OCT), auto-fluorescence (AF) imaging, fundus photography, visual acuity). Laser treatment consisted of 12 single laser pulses of 3ns duration, placed in "clock face" pattern around the mid-macular (5deg radius) of one eye using an energy range of 0.15mJ to 0.45mJ , spot diameter of 400µm, wavelength of 532nm. The patient’s eye with highest risk was treated and main follow-up was performed at 3, 6 and 12mths. Visual field results were used to determine the bilateral regions of greatest dysfunction.

 
Results:
 

13 of the 14 patients that have reached 12mth follow-up showed some level of visual function improvement or drusen reduction, in one or both eyes. The regions of greatest dysfunction in visual function improved significantly in 7 of these patients and the majority of improvement occurred in patients with the greatest pre-treatment dysfunction. VA significantly improved (>5 letters) in 5 patients and some level of drusen reduction occurred in 13 of the patients in one or both eyes. No association was evident between the location of visual function improvements and the location of the laser treatment or the eye treated. Decreased function or other adverse events did not occur in the region of the laser spots.

 
Conclusions:
 

Interim results from this pilot study show that the application of 12 extremely low energy, non thermal, 2RT laser pulses to the mid-macula resulted in visual function improvements in the regions of greatest pre-treatment dysfunction. These regions are likely to be at greatest risk of developing late stage AMD, providing circumstantial evidence that the progress of AMD is being slowed or partially reversed by this laser treatment.

 
Clinical Trial:
 

http://www.anzctr.org.au (ACTRN12609001056280)

 
Keywords: age-related macular degeneration • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×